Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
The available data have suggested a significant association between hypertriglyceridemia and cardiovascular disease. Although atherogenic dyslipidemia in patients with metabolic syndrome is characterized by high triglyceride, low HDL cholesterol and near normal LDL cholesterol levels, lowering LDL cholesterol is the first priority in treating dyslipidemia in patients with metabolic syndrome. The use of statins as monotherapy is still leaving some of these patients with mixed atherogenic dyslipidemia at high risk for coronary events. So, it seems beneficial to add a fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome, especially in patients with inadequately corrected triglyceride levels with statin monotherapy.
Turhan
Hasan
H
Yetkin
Ertan
E
D002995:Clofibric Acid / Q000008:administration & dosage* / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000097:blood / Q000188:drug therapy
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002995:Clofibric Acid